| | | | |
CUSIP No. 01626L105 | | Schedule 13G | | Page 2 of 4 |
ITEM 1. | (a) Name of Issuer: |
Aligos Therapeutics, Inc. (the “Issuer”).
| (b) | Address of Issuer’s Principal Executive Offices: |
One Corporate Drive, 2nd Floor
South San Francisco, CA 94080
ITEM 2. | (a) Name of Person Filing: |
This statement is filed on behalf of Lawrence M. Blatt (the “Reporting Person”).
| (b) | Address or Principal Business Office: |
The business address of the Reporting Person is c/o Aligos Therapeutics, Inc., One Corporate Drive, 2nd Floor, South San Francisco, CA 94080.
| (c) | Citizenship of each Reporting Person is: |
The Reporting Person is a citizen of the United States.
| (d) | Title of Class of Securities: |
Common stock, par value $0.0001 per share (“Common Stock”).
01626L105
Not applicable.
The ownership information below represents beneficial ownership of voting Common Stock of the Issuer as of December 31, 2020, based upon 35,025,572 shares of voting Common Stock outstanding as of November 25, 2020, based on the quarterly report on Form 10-Q filed with the Securities and Exchange Commission on November 25, 2020.
(a) Amount beneficially owned:
Consists of (i) 1,237,298 shares of Common Stock held of record by the Reporting Person; (ii) 113,423 shares of Common Stock held by Lawrence M.